Aquestive Q4 revenues down 4% YoY to $10.7M; guides FY2023 rev $37-41M; AQST-109 pivotal study on track for Q3

Aquestive Therapeutics, Inc.

Q4 2022 total revenues $10.7M vs $11.1M YoY; net loss $12.4M ($0.23/sh) vs $28.9M ($0.72/sh) in Q4 2021.
Full year 2022 total revenues $47.7M, down 6% YoY; net loss $54.4M ($1.12/sh) vs $70.5M ($1.85/sh).
FY2023 guidance: total revenue $37-41M; non-GAAP adjusted EBITDA loss $31-36M.
AQST-109 pivotal study protocol to be submitted to FDA in Q2 2023; study start expected Q3 2023.
Patent litigation settled with BDSI for $8.5M payment to Aquestive; Indivior agreement extended to 2026 with $11.5M one-time payment.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aquestive Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2022.

Period: fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the quarter and fiscal year ended December 31, 2022

View on SEC.gov

Browse all earnings releases →

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-006697

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.